Comparative Cytogenetics in the NCI-60 Panel

The NCI-60 panel represents one of the most extensively characterized collections of human cancer cell lines, offering researchers an invaluable platform for comparative cytogenetic studies. At Cytion, we provide these standardized cell models to facilitate consistent and reproducible research across various laboratories and disciplines.

NCI-60 Panel Scope: 60 Human Cancer Cell Lines Across 9 Tissue Types

The NCI-60 panel, developed by the National Cancer Institute, has become a cornerstone resource in cancer research since its establishment in the 1980s. This comprehensive collection includes 60 meticulously characterized human cancer cell lines derived from nine distinct tissue types: lung, colon, central nervous system, renal, melanoma, ovarian, breast, prostate, and leukemia. At Cytion, we maintain these cell lines under stringent quality control measures to ensure their genetic stability and research reliability. Each line within the panel, such as the A549 cells (lung adenocarcinoma) and DU-145 cells (prostate cancer), has been extensively profiled at the molecular level, providing researchers with valuable baseline data for comparative studies across different cancer types.

Cytogenetic Value: Standardized Models for Chromosomal and Genetic Aberration Studies

The true strength of the NCI-60 panel lies in its unparalleled value for cytogenetic research. These standardized cell models exhibit diverse chromosomal abnormalities that mirror the genetic complexity observed in human tumors. From simple translocations to complex karyotypic rearrangements, each cell line in the panel serves as a defined genetic environment for studying specific aberrations. For instance, MCF-7 cells display characteristic chromosome 7 amplifications, while K562 cells contain the Philadelphia chromosome (a translocation between chromosomes 9 and 22) typical of chronic myeloid leukemia. By working with these well-characterized models, researchers can establish reliable connections between specific genetic alterations and cellular phenotypes, advancing our understanding of how chromosomal aberrations contribute to cancer development and progression.

Research Applications: Drug Screening, Molecular Profiling, and Cancer Mechanism Investigations

The NCI-60 panel has revolutionized cancer research by enabling multiple high-impact applications across diverse scientific disciplines. In drug development, these cell lines serve as primary screening tools for evaluating novel compounds against different cancer subtypes, with over 100,000 compounds tested to date. For molecular profiling studies, the panel offers a comprehensive platform for investigating gene expression patterns, protein interactions, and metabolic pathways within a controlled experimental context. Researchers using HCT116 cells from our collection have made significant discoveries in DNA mismatch repair mechanisms, while studies with LNCaP cells have advanced our understanding of androgen-dependent tumor growth. At Cytion, we continue to support these applications by providing researchers with well-characterized, authenticated cell lines that meet the highest standards for experimental reproducibility and translational relevance.

Comparative Data: Cross-Referencing Genomic Changes and Cellular Responses

The extensive molecular characterization of the NCI-60 panel creates an invaluable resource for comparative data analysis across cancer types. These cell lines have been profiled for DNA copy number variations, gene mutations, mRNA expression, protein levels, and epigenetic modifications, establishing a comprehensive molecular portrait that researchers can leverage to correlate genomic changes with specific cellular responses. When investigators study drug resistance in HeLa cells or invasive properties in MDA-MB-231 cells, they can immediately cross-reference their findings with the existing database of genetic markers and pathway alterations. This comparative approach has led to the identification of key biomarkers for drug sensitivity, the discovery of novel therapeutic targets, and deeper insights into the molecular mechanisms driving cancer progression. By providing these standardized cell lines at Cytion, we enable researchers to contribute to and benefit from this growing body of comparative oncology data.